摘要
目的评价CYP2C9基因多态性对中国心脏机械瓣置换患者华法林初始抗凝效果的影响。方法用Real-time PCR法检测254名中国心脏机械瓣置换患者CYP2C9基因多态性,观察6 d,比较不同CYP2C9基因型患者术后前5 d华法林累积剂量、术后第6 d的INR能否达到治疗窗、INR首次达到治疗窗时间的差异。结果不同CYP2C9基因型患者,术后前5 d华法林累积剂量及首次进入治疗窗的时间均无明显差异(P=0.669,P=0.933);*1/*1基因型患者于术后第6 d进入治疗窗的机会是携带*2和/或*3突变基因患者的4.8倍。结论CYP2C9基因多态性仅影响中国心脏机械瓣置换患者术后第6 d的INR能否进入治疗窗。
Objective To evaluate the effects of CYP2C9 genetic polymorphisms on response to warfarin during initial anticoagulation in Chinese patients with mechanical heart valve replacement. Methods In 254 Chinese valve replacement patients starting warfarin therapy, the CYP2C9 genotypes （CYP2C9 ＊ 1, ＊ 2, and ＊ 3） were assessed. The study outcomes included the time to the first International Normalized Ratio （INR） reach the therapeutic range, the total warfarin doses in initial 5 days, and whether INR within the therapeutic range in the day 6. Results Compared with patients with the ＊ 1/＊ 1 genotype, patients with the ＊ 2 or ＊ 3 genotype of CYP2C9 had the same time to the first INR reach the therapeutic range （P = 0. 933） and no difference in total warfarin doses in initial 5 days （P= 0. 669）. However, the CYP2C9 genotype was a significant predictor of INR within the therapeutic range in the day 6. Conclusion CYP2C9 genetic polymorphisms only affected INR within the therapeutic range in the day 6 in Chinese patients with mechanical heart valve replacement.
出处
《中国临床药理学杂志》
CAS
CSCD
北大核心
2013年第1期3-5,41,共4页
The Chinese Journal of Clinical Pharmacology
基金
国家科技重大专项基金资助项目(2011ZX09304)
心血管创新药物临床研究技术平台建设基金资助项目(2012ZX09303008-001)
